Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WN/DEN4Δ30 Vaccine in Adults 50-65
NCT02186626Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2014
- Primary completion
- Jul 2016
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in West Nile virus infection (WNV) comparing WN/DEN4Δ30 Vaccine with Placebo (2 arms). Primary endpoints: Frequency of vaccine-related adverse events at Day 360 and Measurement of anti-WNV neutralizing antibody at Day 360. Started Feb 2014; status: completed.
02
Drugs
WN/DEN4Δ30
03
Conditions
West Nile virus infection (WNV)
Beyond the preview
Go deeper on NCT02186626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186626.